HENAN LINGRUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.08 CNY | -0.94% |
|
+5.29% | +34.89% |
| Sales 2023 * | 3.46B 477M | Sales 2024 * | 3.96B 547M | Capitalization | 13.02B 1.8B |
|---|---|---|---|---|---|
| Net income 2023 * | 537M 74.17M | Net income 2024 * | 641M 88.53M | EV / Sales 2023 * | 3.77 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 3.28 x |
| P/E ratio 2023 * |
24.3
x | P/E ratio 2024 * |
20.4
x | Employees | 2,524 |
| Yield 2023 * |
3.21% | Yield 2024 * |
3.81% | Free-Float | 74.14% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.94% | ||
| 1 week | +5.29% | ||
| Current month | +7.60% | ||
| 1 month | +10.17% | ||
| 3 months | +31.44% | ||
| 6 months | +36.97% | ||
| Current year | +34.89% |
1 week
21.91
23.75
1 month
20.1923.75
Current year
16.1523.75
1 year
14.3023.75
3 years
8.2423.75
5 years
7.6623.75
10 years
5.8123.75
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Xiong
CEO | Chief Executive Officer | 40 | - |
Peng Yu
DFI | Director of Finance/CFO | 55 | - |
Jia Shu Jiang
BRD | Director/Board Member | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Xiong
CEO | Chief Executive Officer | 40 | - |
Zhi Jun Zhao
BRD | Director/Board Member | 53 | 20-06-04 |
Xi Zhen Wu
BRD | Director/Board Member | 60 | 06-04-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | -1.38% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 23.08 | -0.94% | 7,387,557 |
| 24-04-17 | 23.3 | +2.19% | 10,416,720 |
| 24-04-16 | 22.8 | -1.17% | 8,783,225 |
| 24-04-15 | 23.07 | +4.01% | 10,428,900 |
| 24-04-12 | 22.18 | +1.19% | 7,820,776 |
End-of-day quote Shanghai S.E., April 17, 2024
More quotes
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
23.08
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +34.89% | 1.8B | |
| +40.29% | 6.16B | |
| -15.73% | 4.49B | |
| -9.40% | 3.17B | |
| -1.60% | 3.01B | |
| -1.23% | 2.57B | |
| -11.37% | 1.62B | |
| -5.02% | 1.56B | |
| -13.21% | 1.53B | |
| +25.23% | 1.29B |
- Stock Market
- Equities
- 600285 Stock
